These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12553480)

  • 1. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.
    Yazdanpanah Y; Goldie SJ; Losina E; Weinstein MC; Lebrun T; Paltiel AD; Seage GR; Leblanc G; Ajana F; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
    Antivir Ther; 2002 Dec; 7(4):257-66. PubMed ID: 12553480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.
    Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A
    AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric HIV costs across three treatment eras from 1986 to 2007.
    Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
    Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
    Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
    Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost of HIV treatment in highly active antiretroviral therapy in Japan].
    Kimura H
    Nihon Rinsho; 2002 Apr; 60(4):813-6. PubMed ID: 11968794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected Lifetime Healthcare Costs Associated with HIV Infection.
    Nakagawa F; Miners A; Smith CJ; Simmons R; Lodwick RK; Cambiano V; Lundgren JD; Delpech V; Phillips AN
    PLoS One; 2015; 10(4):e0125018. PubMed ID: 25901355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.
    Yazdanpanah Y; Goldie SJ; Paltiel AD; Losina E; Coudeville L; Weinstein MC; Gerard Y; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
    Clin Infect Dis; 2003 Jan; 36(1):86-96. PubMed ID: 12491207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.